A New Approach to Covid-19 Vaccine Development May Hold Promise for Nasal Delivery.
Scientists in Germany claim to have made breakthroughs in developing a nasal vaccine that can effectively combat the Covid-19 virus by targeting its entry point into the body. In laboratory experiments, researchers tested a live but weakened form of the coronavirus on hamsters and found that it was able to create "sterilizing immunity" - effectively eliminating the virus from the animals' upper airways.
The nasal vaccine works by boosting mucosal immunity in the tissues lining the upper respiratory tract, where the virus enters the body. This approach aims to provide a more effective defense against Covid-19 than current vaccines that focus on inducing systemic immunity through injection. By targeting the virus at its entry point, researchers hope to prevent infection altogether.
While the results of these experiments are promising, scientists caution that further testing is still needed before the vaccine can be widely used. The nasal vaccine needs to undergo rigorous clinical trials in humans and address concerns about its effectiveness against evolving variants of the virus.
Scientists in Germany claim to have made breakthroughs in developing a nasal vaccine that can effectively combat the Covid-19 virus by targeting its entry point into the body. In laboratory experiments, researchers tested a live but weakened form of the coronavirus on hamsters and found that it was able to create "sterilizing immunity" - effectively eliminating the virus from the animals' upper airways.
The nasal vaccine works by boosting mucosal immunity in the tissues lining the upper respiratory tract, where the virus enters the body. This approach aims to provide a more effective defense against Covid-19 than current vaccines that focus on inducing systemic immunity through injection. By targeting the virus at its entry point, researchers hope to prevent infection altogether.
While the results of these experiments are promising, scientists caution that further testing is still needed before the vaccine can be widely used. The nasal vaccine needs to undergo rigorous clinical trials in humans and address concerns about its effectiveness against evolving variants of the virus.